An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Staging investigations following the diagnosis of Ewing sarcoma may include chest computerized tomography (CT), technetium bone scintigraphy (bone scan), [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography (FDG‐PET) scan, and bone marrow biopsy and aspiration (BMA/Bx). Each of these staging investigations provides complementary prognostic information, however the optimal combination of staging investigations is not clear. Procedure: We conducted a retrospective study of 91 patients diagnosed with Ewing sarcoma and consecutively treated at our medical facilities between January 1, 2001 and December 31, 2011. We compared the radiologist's interpretations of staging FDG‐PET and bone scans. We additionally compared the results of imaging evaluations to bilateral and unilateral BMA/Bx. Results: We found FDG‐PET and bone scan to have an examination‐based concordance rate of 98% (one discordant case with a positive FDG‐PET and negative bone scan). The region‐based concordance rate for the imaging modalities was 97% for all cases and 63% for metastatic cases. The ipsilateral concordance rate for BMA/Bx was 98% with BMBx detecting metastases in seven cases and BMA detecting metastases in four cases. The left versus right concordance rates for BMBx and BMA were 98% and 97%, respectively. In all cases where bone marrow metastases were detected by BMA or BMBx, FDG‐PET and bone scan detected osseous metastases. Conclusions: Our study indicates FDG‐PET may be sufficient for initial screening for osseous metastases and identified all patients who also have bone marrow metastases. If osseous metastases are detected, a bone scan can detect additional osseous lesions and BMBx may indicate prognostic bone marrow metastases. Pediatr Blood Cancer 2013; 60: 1113–1117. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meyer, J. S., Nadel, H. R., Marina, N., Womer, R. B., Brown, K. L. B., Eary, J. F., Gorlick, R., Grier, H. E., Randall, R. L., Lawlor, E. R., et al. (2008) · Pediatric Blood & Cancer · doi:10.1002/pbc.21596 · Cited by 180 · cited 13×
“A consensus statement from the Children’s Oncology Group Bone Tumor Committee requires chest CT, bone scan, and recommends FDG-PET, without comment upon BMA/Bx [11].”
BackgroundInfluential
Cited by
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617
Self-citationStrauss, S. J., Frezza, A. M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., Bonvalot, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1995 · Cited by 513
Self-citationUK guidelines for the management of bone sarcomas
On behalf of the British Sarcoma Group, Gerrand, C., Athanasou, N., Brennan, B., Grimer, R., Judson, I., Morland, B., Peake, D., Seddon, B., & Whelan, J. (2016) · Clinical Sarcoma Research · doi:10.1186/s13569-016-0047-1 · Cited by 258
Metadata
- Authors
- Newman, E. N., Jones, R. L., & Hawkins, D. S.
- Venue
- Pediatric Blood & Cancer
- Publisher
- Wiley
- Published
- 2012-11-28
- Volume
- 60
- Issue
- 7
- Pages
- 1113-1117
- ISSN
- 1545-5009 (ISSN-L)
- 1545-5017
- OpenAlex
- W2094280178
- Cited by
- 88
- References
- 1
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma. https://app.cochat.ai/papers/10.1002/pbc.24406
- The paper
- Newman, E. N., Jones, R. L., & Hawkins, D. S. (2013). An evaluation of [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomography, bone scan, and bone marrow aspiration/biopsy as staging investigations in Ewing Sarcoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.24406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.